The relationship between dyslipidemia and NAFLD is bidirectional, as an increase in circulating plasma lipids can result in ectopic fat deposition in liver tissue, and hepatic fat accumulation may contribute to an atherogenic dyslipidemic profile through e.g., increased very-low density lipoprotein (VLDL)-secretion [23] and possibly by increased CETP-activity and decreased expression of the LDL-receptor [14,24,25]. The gene discussed is CETP; the disease is metabolic dysfunction-associated steatotic liver disease.